Discover how autoimmune conditions target joints, causing pain and inflammation. Learn about 7 conditions, symptoms, and ...

Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented ...

Called enpatoran, the agent targets the Toll-like receptor (TLR) species 7 and 8. Some 50%-60% of patients with systemic ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...

When receiving a diagnosis of a rheumatic musculoskeletal disease (RMD), people need a lot of information. Some need it all ...

Germany’s Merck KGaA has presented detailed results from cohort B of the global Phase II WILLOW study of enpatoran, an ...

BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy ...

The leading causes of readmission among patients who received THA included sepsis (14.6%), nonseptic infections (14.8%), cardiovascular events (11.2%), and pulmonary complications (8.4%). Common ...

The incidence and prevalence of CTD-ILD in the US is most common among women and older individuals, affecting approximately ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...